替罗非班在急性冠脉综合征(PCI)患者术前不同时期应用的临床价值分析  

Clinical efficacy of tirofiban usage in different period of time before surgery for patients with PCI

作　　者：李斌[1] 

机构地区：[1]四川省都江堰市中医医院心血管内科,四川都江堰611830

出　　处：《中国医药科学》2014年第9期97-99,共3页China Medicine And Pharmacy

摘　　要：目的探讨替罗非班(tirofiban)在急诊PCI(percutaneous coronary intervention,PCI)患者术前不同时期应用的临床价值。方法回顾性分析2010年8月~2013年11月四川省都江堰市人民医院急诊行PCI术患者98例,其中PCI术前急诊即开始应用替罗非班者47例(术前组),PCI术中应用者51例(术中组),分析两组患者PCI术后24h心肌酶CK-MB和cTNI有无差别;两组患者术后主要心血管并发症有无差别。结果术前组PCI术后24h心肌酶显著低于术中组(t=3.09/2.66,P<0.05);术前组患者术后主要心血管事件明显低于对照组(x2=4.01,P<0.05)。结论急性冠脉综合征患者术前急诊早期应用替罗非班可降低患者不良心血管事件的发生风险,改善心肌酶指标。Objective To evaluate the clinical efficacy of tirofiban in different period of time before surgery for patients with acute coronary syndrome who received PCI. Methods 98 patients from Aug 2010 to Nov 2013 with acute coronary syndrome treated with PCI were analyzed respectively in the department of emergency in the People''s Hospital of Dujiangyan. Of the included 98 subjects 47 patients treated by tirofiban prior the PCI(treatment group) and 51 cases treated by tirofiban intra the PCI(control group). And the major cardiovascular events and the CK-MB, cTNM was compared between the two groups. Results The enzyme in the preoperative group of PCI was significantly lower than that in the intraoperative group (t=3.09/2.66, P<0.05);The major cardiovascular events and cardiac enzymes in treatment group was much lower than that in the control group(x2=4.01,P<0.05). Conclusion Application tirofiban as early as possible can significantly decrease the major cardiovascular risk and protect the heart muscle.

关 键 词：替罗非班 急性冠脉综合征 临床疗效 

分 类 号：R541.4[医药卫生—心血管疾病]